Keyphrases
PARP Inhibitor (PARPi)
73%
Laboratory-developed Test
66%
RAD51
66%
Homologous Recombination Deficiency
66%
Homologous Recombinant
66%
Inhibitor Sensitivity
66%
Bloom Helicase
26%
Progression-free Survival
22%
Genomic Instability
20%
RAD51 Foci
14%
Open Standards
14%
Ovarian Cancer
14%
BRCA Testing
13%
Cross-tabulation Analysis
7%
Focus Detection
7%
Attention Analysis
7%
ENGOT
7%
Tumor
7%
Spearman Correlation
7%
Fisher's Exact Test
7%
Homologous Recombination Proficient
7%
Cox Regression
7%
Survival Analysis
7%
Clinical Benefit
7%
Inhibitor Therapy
7%
Comparative Calculation
6%
Diagnostic Flow
6%
Comparative Statistics
6%
Copenhagen
6%
Sweden
6%
Clinical Application
6%
Turnaround Time
6%
Breast Cancer
6%
National Guidelines
6%
BRCA Status
6%
University Hospital
6%
Denmark
6%
Denmark-Norway
6%
Ovarian Cancer Patients
6%
Nordic Countries
6%
Inhibitor Treatment
6%
Finland
6%
Targeted Treatment
6%
Micronucleation
6%
Nuclear Chromatin
6%
Biochemistry, Genetics and Molecular Biology
Poly ADP Ribose Polymerase
100%
Genome Instability
75%
RAD51
66%
Homologous Recombination
66%
Ribosomal DNA
66%
Turnaround Time
33%
Progression Free Survival
25%
Chromatin
7%
Immunology and Microbiology
Genomic Instability
75%
Replication Factor A
66%
Homologous Recombination
66%
Turnaround Time
33%
Chromatin
33%
Micronucleus
33%
Bloom Syndrome
33%
Progression Free Survival
25%